134 related articles for article (PubMed ID: 36892250)
1. Long-term storage protocol of reagent red blood cells treated with 0.01M dithiothreitol (DTT) for pre-transfusion testing of patients receiving anti-CD38 therapy, daratumumab.
Li Y; Li C; Zhang L; Li J; Li Q; Ouyang H; Luo J; Zhu L; Cai K
Hematology; 2023 Dec; 28(1):2186037. PubMed ID: 36892250
[TBL] [Abstract][Full Text] [Related]
2. Stability guidelines for dithiothreitol-treated red blood cell reagents used for antibody detection methods in patients treated with daratumumab.
Disbro WL
Immunohematology; 2017 Sep; 33(3):105-109. PubMed ID: 29043827
[TBL] [Abstract][Full Text] [Related]
3. Extending shelf life of dithiothreitol-treated panel RBCs to 28 days.
Sigle JP; Mihm B; Suna R; Bargetzi M
Vox Sang; 2018 May; 113(4):397-399. PubMed ID: 29512161
[TBL] [Abstract][Full Text] [Related]
4. [Application of Modified DTT Methods to Reduce the Interference of Daratumumab on Serological Detection].
Li YY; Zhang L; Cai K; Wu MH; Zhu LR; Li CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(5):1543-1549. PubMed ID: 37846714
[TBL] [Abstract][Full Text] [Related]
5. A newly devised flow cytometric antibody binding assay helps evaluation of dithiothreitol treatment for the inactivation of CD38 on red blood cells.
Furumaki H; Takeshita A; Ohto H; Yamada C; Fujihara H; Ishizuka K; Shibata H; Shinba T; Nemoto N; Ino K; Ozawa A; Watanabe H; Kawabata K; Obata Y
Vox Sang; 2021 Jul; 116(6):725-734. PubMed ID: 33314130
[TBL] [Abstract][Full Text] [Related]
6. Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method).
Hosokawa M; Kashiwagi H; Nakayama K; Sakuragi M; Nakao M; Morikawa T; Kiyokawa T; Aochi H; Nagamine K; Shibayama H; Tomiyama Y
Transfusion; 2018 Dec; 58(12):3003-3013. PubMed ID: 30267414
[TBL] [Abstract][Full Text] [Related]
7. Blood component administration to multiple myeloma patients treated with daratumumab: suggesting a novel approach with use of 0.1 M dithiothreitol.
Pandey P; Setya D; Kaul E; Ranjan S; Singh MK; Shankar A
Immunohematology; 2020 Dec; 36(4):157-165. PubMed ID: 33544622
[TBL] [Abstract][Full Text] [Related]
8. Mitigation of therapeutic anti-CD38 antibody interference with fab fragments: How well does it perform?
Habicht CP; Ridders M; Grueger D; Adolph S; Immenschuh S; Schneeweiss C
Transfusion; 2023 Apr; 63(4):808-816. PubMed ID: 36707937
[TBL] [Abstract][Full Text] [Related]
9. A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing.
Chinoca Ziza KN; Paiva TA; Mota SR; Dezan MR; Schmidt LC; Brunetta DM; Ricci G; Basques FV; Barroso-Duarte F; Rocha V; Mendrone-Junior A; Dinardo CL
Transfusion; 2019 May; 59(5):1827-1835. PubMed ID: 30779172
[TBL] [Abstract][Full Text] [Related]
10. Thirty-three-day storage of dithiothreitol-treated red blood cells used to eliminate daratumumab interference in serological testing.
Lorenzen H; Lone Akhtar N; Nielsen M; Svendsen L; Andersen P
Vox Sang; 2018 Oct; 113(7):686-693. PubMed ID: 30043984
[TBL] [Abstract][Full Text] [Related]
11. Resolving the daratumumab interference with blood compatibility testing.
Chapuy CI; Nicholson RT; Aguad MD; Chapuy B; Laubach JP; Richardson PG; Doshi P; Kaufman RM
Transfusion; 2015 Jun; 55(6 Pt 2):1545-54. PubMed ID: 25764134
[TBL] [Abstract][Full Text] [Related]
12. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing.
Chapuy CI; Aguad MD; Nicholson RT; AuBuchon JP; Cohn CS; Delaney M; Fung MK; Unger M; Doshi P; Murphy MF; Dumont LJ; Kaufman RM;
Transfusion; 2016 Dec; 56(12):2964-2972. PubMed ID: 27600566
[TBL] [Abstract][Full Text] [Related]
13. Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens.
Phou S; Costello C; Kopko PM; Allen ES
Transfusion; 2021 Jul; 61(7):2054-2063. PubMed ID: 33960433
[TBL] [Abstract][Full Text] [Related]
14. [Pre-Transfusion Testing and Transfusion Strategy in Patients with Multiple Myeloma after Daratumumab Treatment].
Fang XM; Guo ZW; Yang JQ; Yang B; Xiao YH; Liu Y; Xu ML
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1595-1600. PubMed ID: 34627446
[TBL] [Abstract][Full Text] [Related]
15. New method for overcoming the interference produced by anti-CD38 monoclonal antibodies in compatibility testing.
Izaguirre EC; Del Mar Luis-Hidalgo M; González LL; Castaño CA
Blood Transfus; 2020 Jul; 18(4):290-294. PubMed ID: 32530397
[TBL] [Abstract][Full Text] [Related]
16. Dithiothreitol treatment of red blood cells.
Bub CB
Immunohematology; 2019; 33(4):170-172. PubMed ID: 34841820
[TBL] [Abstract][Full Text] [Related]
17. Dithiothreitol treatment of red blood cells.
Bub CB
Immunohematology; 2017 Dec; 33(4):170-172. PubMed ID: 29378150
[TBL] [Abstract][Full Text] [Related]
18. Use of standard laboratory methods to obviate routine dithiothreitol treatment of blood samples with daratumumab interference.
Lintel NJ; Brown DK; Schafer DT; Tsimba-Chitsva FM; Koepsell SA; Shunkwiler SM
Immunohematology; 2017 Jan; 33(1):22-26. PubMed ID: 28425752
[TBL] [Abstract][Full Text] [Related]
19. Use of an in-house trypsin-based method to resolve the interference of daratumumab.
Ibeh N; Baine I; Rudon LF; Lomas-Francis C; Jhang JS; Galdon P; Westhoff CM; Velliquette RW; Arinsburg SA
Transfusion; 2021 Oct; 61(10):3000-3007. PubMed ID: 34472116
[TBL] [Abstract][Full Text] [Related]
20. Better resolving of anti-CD38 antibody interference with blood compatibility testing by using manual polybrene method compared with dithiothreitol-pretreatment indirect antiglobulin test.
Feng CC; Chang CW; Lien ZY; Lin JA; Chen TT; Yeh SP
J Clin Lab Anal; 2023 Apr; 37(8):e24891. PubMed ID: 37161608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
